echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Once the new crown vaccine is mass-vaccinated, the EU is concerned that supplies such as syringes may be in short supply.

    Once the new crown vaccine is mass-vaccinated, the EU is concerned that supplies such as syringes may be in short supply.

    • Last Update: 2020-08-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The European Union has warned that it may face a shortage of medical supplies such as syringes and protective clothing once the new crown vaccine begins mass vaccinations, urging member states to consider joint procurement.
    Reuters on July 30, citing a summary report from the European Commission, reported: "Once the development of the new coronavirus vaccine is successful, there may not be (sufficient) syringes and other medical supplies ... There may be a shortage".
    the European Commission last week called a meeting of public health experts from EU member states to publish the summary report on its website.
    report shows that the EU asked member states about stocks of personal protective equipment such as syringes, alcohol and face masks and urged them to consider joint procurement.
    joint procurement scheme swayed EU governments from a "price war" to order them at more favourable prices.
    reported that several representatives of Italy and the Netherlands were interested in joint procurement.
    a spokesman for the Dutch National Institutes of Health confirmed the EU's joint procurement plan, saying the Netherlands had started a separate process of ordering 10 million syringes and needles.
    a variety of new crown vaccines are being developed, and its effectiveness has yet to be confirmed.
    countries have begun to seek to ensure that their countries have adequate access to vaccines.
    Reuters reported that the UK has so far signed four agreements with a number of pharmaceutical companies to pre-order 250 million doses of the new crown vaccine, the largest pre-purchased dose of the vaccine.
    U.S. Pfizer Inc. and Germany's Bio-New Technologies Corp. confirmed Tuesday that the U.S. government will pay $1.95 billion for 10million doses of the vaccine for 50 million people if clinical trials prove the vaccine is safe and effective.
    Reuters reported that once the vaccine is proven to be effective, the mass production and distribution of the vaccine could be an obstacle to mass vaccination.
    in addition, the EU has asked member states to consider jointly sourcing more flu vaccines and expanding vaccinations to reduce the risk of simultaneous outbreaks of influenza and the new crown this fall.
    the EU has contacted flu vaccine manufacturers to ask if more vaccines could be supplied, according to a summary of the EU's open meeting.
    EU member states could decide by July 24 whether to join the joint flu vaccine procurement programme.
    Bao Xuelin Source: Xinhua News Agency, !-- Content Presentation Ends- !-- Determine signed-up
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.